A gain-of-function polymorphism in human neuropeptide Y (NPY) gene (rs16139) associates with metabolic disorders and earlier onset of type 2 diabetes (T2D). Similarly, mice overexpressing NPY in noradrenergic neurons (OE-NPY DBH ) display obesity and impaired glucose metabolism. In this study, the metabolic syndrome-like phenotype was characterized and mechanisms of impaired hepatic fatty acid, cholesterol and glucose metabolism in pre-obese (2-month-old) and obese (4-7-month-old) OE-NPY DBH mice were elucidated. Susceptibility to T2D was assessed by subjecting mice to high caloric diet combined with low-dose streptozotocin. Contribution of hepatic Y1-receptor to the phenotype was studied using chronic treatment with an Y1-receptor antagonist, BIBO3304. Obese OE-NPY DBH mice displayed hepatosteatosis and hypercholesterolemia preceded by decreased fatty acid oxidation and accelerated cholesterol synthesis. Hyperinsulinemia in early obese state inhibited pyruvate-and glucose-induced hyperglycemia, and deterioration of glucose metabolism of OE-NPY DBH mice developed with aging. Furthermore, streptozotocin induced T2D only in OE-NPY DBH mice. Hepatic inflammation was not morphologically visible, but upregulated hepatic anti-inflammatory pathways and increased 8-isoprostane combined with increased serum resistin and decreased interleukin 10 pointed to increased NPY-induced oxidative stress that may predispose OE-NPY DBH mice to insulin resistance. Chronic treatment with BIBO3304 did not improve the metabolic status of OE-NPY DBH mice. Instead, downregulation of beta-1-adrenoceptors suggests indirect actions of NPY via inhibition of sympathetic nervous system. In conclusion, changes in hepatic fatty acid, cholesterol and glucose metabolism favoring energy storage contribute to the development of NPY-induced metabolic syndrome, and the effect is likely mediated by changes in sympathetic nervous system activity.
Introduction
Besides its orexigenic nature in the hypothalamus (Zarjevski et al. 1993 , Yang et al. 2009 , Sousa-Ferreira et al. 2011 , neuropeptide Y (NPY) induces obesity and metabolic alterations independent of hyperphagia. In humans, a gain-of-function polymorphism in NPY gene (rs16139, p.L7P), which increases NPY secretion especially upon sympathetic activation (Kallio et al. 2001 , Mitchell et al. 2008 , has been associated with traits of the metabolic syndrome, i.e. weight gain, hypercholesterolemia, impaired glucose tolerance (IGT), insulin resistance (IR), earlier onset of type 2 diabetes (T2D) and increased risk of diabetes-related vascular complications (Karvonen et al. 1998 , Pihlajamaki et al. 2003 , Nordman et al. 2005 , van Rossum et al. 2006 , Ukkola & Kesaniemi 2007 , Jaakkola et al. 2009 , Yeung et al. 2011 , Masoudi-Kazemabad et al. 2013 without an association to increased food intake (Karvonen et al. 2006 , Yeung et al. 2011 .
The mechanisms whereby NPY alters energy metabolism have been elucidated in animal models. Central NPY is known to suppress the sympathetic tone, energy expenditure and brown adipose tissue (BAT) thermogenic activity, and to increase lipogenesis in white adipose tissue (WAT) (Egawa et al. 1991 , Zarjevski et al. 1993 , Shi et al. 2013 ). An important source of NPY in the periphery is the sympathetic nervous system (SNS), and NPY levels are increased upon stress (Ekblad et al. 1984) . Consistently, NPY has been implicated in the stressinduced obesity, directly affecting the adipogenic and lipogenic regulation of WAT (Kuo et al. 2007 , Zhang et al. 2014 . In addition, chronic peripheral NPY administration induces obesity (Xie et al. 2012) , and knockdown of peripheral NPY Y1-or Y2-receptors protects from dietinduced obesity by changing fuel oxidation (Zhang et al. 2010 , Shi et al. 2011 .
The mechanisms of NPY-induced hypercholesterolemia, IGT or earlier onset of T2D in humans are still unknown, but it can be hypothesized that hepatosteatosis plays a role in the NPY-induced metabolic and vascular diseases. Hepatosteatosis is suggested to be the hepatic manifestation of the metabolic syndrome and the actual cause of the related cardiovascular diseases (Lu et al. 2013) . It predicts the incidence of T2D (Vozarova et al. 2002 , Lee et al. 2003 , and together with diabetes increases the risk for cardiovascular events (Targher et al. 2005) . In various murine models, NPY has been shown to contribute to hepatic lipogenesis, VLDLtriglyceride (TG) and VLDL-cholesterol secretion, fatty acid (FA) oxidation and increased serum cholesterol levels (Zarjevski et al. 1993 , Stafford et al. 2008 , Zhang et al. 2010 , Bruinstroop et al. 2012 , Xie et al. 2012 , Zhang et al. 2014 ), but it is not known, whether chronic excess of NPY causes hepatosteatosis, or which hepatic mechanisms contribute to dyslipidemias and development of the metabolic syndrome.
The mouse model overexpressing NPY in central and peripheral noradrenergic neurons driven by dopaminebeta-hydroxylase (DBH) gene promoter (OE-NPY DBH ) presents a model of NPY-induced metabolic syndromelike phenotype without hyperphagia (Ruohonen et al. 2008 . Thus, it allows studying the mechanisms of NPY in SNS and brainstem in the pathogenesis of obesity and metabolic disturbances. Heterozygous OE-NPY DBH mice display increased fat mass and hepatic TGs, and subsequently develop hyperinsulinemia and IGT (Ruohonen et al. 2008) . Homozygous OE-NPY DBH mice display a more severe obese phenotype, and the suggested mechanisms are direct effects of NPY on adipocytes, and decreased sympathetic activity to adipose tissues (Ruohonen et al. 2008 ). In the current study, we aimed to elucidate the effects of noradrenergic NPY on hepatic FA, cholesterol and glucose metabolism, to define their contribution to the development of the hepatosteatosis, hypercholesterolemia and IGT, and finally, to characterize whether the changes are due to direct effects of NPY mediated via hepatic Y-receptors or due to changes in SNS activity.
Materials and methods

General
Generation of the transgenic heterozygous and homozygous OE-NPY DBH mice has been described in detail elsewhere (Ruohonen et al. 2008 . Transgenic mice were maintained on a C57BL/6N inbred background, and either heterozygote and wild-type (WT) littermates, or 1 st -3 rd generation of WT and homozygous mice originating from the same heterozygous breedings were used. The mice were kept in an animal room maintained at 21 ± 3ºC with fixed 12-h light:12-h darkness cycle. Standard rodent chow diet (SDS, Essex, UK) and tap water were available ad libitum. At termination, 4-h-fasted mice were anesthetized with ketamine (75 mg/kg i.p. Ketaminol, Intervet Oy, Finland) and medetomidine (1 mg/kg i.p. Cepetor, ScanVet Oy, Finland), 234:1 and serum was obtained by cardiac puncture. Tissues were collected and weighed, and stored in −70ºC. The experimental procedures were approved by the national animal care and use committee (ELLA). Animal care was in accordance with the guidelines of the International Council of Laboratory Animal Science (ICLAS).
Study 1. Characterization of the phenotype of obese OE-NPY DBH mice
Liver fat content and histology, and serum cholesterols were analyzed in 4-and 7-month-old male and female homozygous OE-NPY DBH mice. These mice were previously shown to display 1.5-fold increase in WAT weight and a decrease in serum TG levels compared to WT controls. They develop IGT, IR, fasting hyperinsulinemia and hyperleptinemia, which are most pronounced in 7-month-old males .
Study 2. Mechanisms leading to metabolic syndrome-like phenotype in OE-NPY DBH mice
Mechanisms of hepatosteatosis, hypercholesterolemia and IGT were first elucidated by analyzing changes in hepatic mRNA expression profile preceding any metabolic disturbances (pre-obese 2-month-old heterozygous mice, n = 4-5/group) that might suggest causal mechanisms. This was followed by in vivo functional assays verifying the findings in the gene expression. Homozygous male mice were used due to their more severe metabolic phenotype, except in cholesterol studies where female mice were used due to their lower level of hepatosteatosis that could induce hypercholesterolemia independent of NPY. Betaoxidation assay (supplementary information, see section on supplementary data given at the end of this article) was carried out in 2-month-old mice (n = 6-9/group) that do not yet show signs of hepatosteatosis. Cholesterol absorption and synthesis assay (supplementary information) was carried out in 6-month-old mice (n = 5-10/group), and glucose-stimulated insulinemia and hepatic glucose production in early (at 4 months) and in established obese states (at 7 months) (n = 6-11/group). Oxidative stress and inflammation as potential causes of IR were analyzed in pre-obese (at 2 months) and obese (at 5 and 7 months) states (n = 3-10/group).
Glucose, pyruvate and insulin tolerance tests
To study insulin secretion during glucose tolerance test mice were implanted with a carotid artery catheter under 2% isoflurane anesthesia and buprenorfine analgesia (0.1 mg/kg, s.c., twice a day for 2 days, Temgesic, ScheringPlough, Brussels, Belgium). After 3-day recovery, fasted mice (4 h) received glucose (1 g/kg, i.p.), and arterial blood samples (25 µL) were collected using an automated blood sampling device (AccuSampler®µ, VeruTech, Lund, Sweden) from awake, freely moving mice. Another set of mice were challenged for glucose (1 g/kg) and pyruvate (2 g/kg, Sigma-Aldrich), which were injected (i.p.) after a 4 and 4 or 6 h fast, respectively. Blood glucose was measured with a glucose meter (Precision Xtra Glucose Monitoring Device, Abbott Diabetes Care, Abbot Park, IL, USA) at baseline and after the injection at the indicated time points.
Study 3. Susceptibility to T2D
The susceptibility to T2D was studied by disrupting pancreatic insulin secretion with STZ in mice with IR due to high caloric diet that induces obesity in a similar manner in OE-NPY DBH and WT mice, but is not sufficient to induce T2D in OE-NPY DBH mice (Ruohonen et al. 2012) . Homozygous male OE-NPY DBH of 16-week-old and WT mice (n = 7/group) subjected to western diet (41% kcal fat, 43% kcal carbohydrate, 17% kcal protein, D12079B, Research Diets, New Brunswick, NJ, USA) for 3 weeks were administered a low-dose [40 mg/kg in 7.5 mg/ml Na-Citrate solution (pH 4.5), i.p.) of STZ (Sigma-Aldrich] after a 4-h fast on 3 consecutive days (week 0), followed by a single dose every 4.5 weeks to maintain hyperglycemia. Weight gain and fasting (4 h) tail vein blood glucose were monitored weekly and fat mass by quantitative NMR (EchoMRI-700, Echo Medical Systems, Houston, TX, USA) at weeks -3 and 9. Glucose (GTT) (1 g/kg glucose i.p. after a 4-h fast) and insulin tolerance tests (ITT) (1 IU/kg insulin i.p. after a 1-h fast) were performed at weeks 10 and 12, respectively. Tissues were collected at week 13.
Study 4. Peripheral Y1R-antagonist treatment
To study whether hepatic Y-receptors, or modulation of SNS activity, mediate the effects of noradrenergic NPY, expressions of hepatic Y-and adrenergic receptors were analyzed. The contribution of Y1-receptors was studied using a peripherally acting Y1R-antagonist, BIBO3304 trifluoroacetate (Tocris Bioscience, Bristol, UK) (1 mg/kg/ day, i.p.) (Dozio et al. 2007 , Yuzuriha et al. 2007 or vehicle (DMSO, Tween® 80 (Fisher Scientific, Fair Lawn, NJ, USA) and 0.9% NaCl, 1:1:18), which were administered to 20-week-old homozygous male OE-NPY DBH and WT 234:1 mice (n = 10-13/group) over 30 days preceded by a 2-week habituation with daily saline injections. Food intake was monitored weekly and weight gain twice a week. Body composition was measured on days -14, 0 and 30 by quantitative NMR followed by tissue collection (after 3-h fast). As peripheral Y1-knockdown was shown to reduce respiratory exchange ratio (RER) without significantly affecting adiposity (Zhang et al. 2010) , the effects of BIBO3304 vs vehicle (for 7 days preceded by 7 days habituation) were elucidated on 24-h energy expenditure (EE), RER and activity in 3-month-old WT mice (n = 4/ group) with an indirect calorimetry (Oxylet System, Panlab, Barcelona, Spain).
Biochemical assays
Serum insulin levels were determined with Ultrasensitive Mouse Insulin ELISA Kit (Mercodia AB, Uppsala, Sweden), non-esterified fatty acids (NEFA) with the NEFA-HR(2) kit (Wako Diagnostics, Richmond, VA, USA), and total cholesterol and cholesterol fractions with a Cholesterol Quantitation Kit and with a HDL and LDL/VLDL Cholesterol Quantification Kit (Biovision) (Study 1) or Cholesterol Fluorometric Assay kit (Cayman Chemical) (Study 4). Serum and liver TGs were measured with TR0100 Serum triglyceride determination kit (Sigma-Aldrich). The hepatic TGs were analyzed from lipids purified with Folch method (Folch et al. 1957 ) (Study 1), or directly from the liver tissue homogenized in PBS containing 0.1% NP-40 (Study 4).
Oxidative stress markers were analyzed in plasma, liver and urine. Total peroxyl radical trapping antioxidant potential in plasma was measured as previously described (Ahotupa et al. 1997) . Hepatic diene conjugation was measured according to a previously published method (Corongiu & Milia 1983 
Histology
Liver histology was analyzed from formalin-fixed samples embedded in paraffin, sectioned (5 µm) every 200 µm on microscopic slides, stained with hematoxylin and eosin (H&E) or periodic acid-Schiff (PAS), and analyzed under a standard light microscope. Hepatosteatosis was graded according to (Cabezas et al. 2012) . Liver cryosections (10 µm) were stained with Oil Red O (ORO) to visualize the lipid droplets. Pancreatic sections were stained with H&E. The areas of the islets of Langerhans (n = 69-115/group) were measured using the Cell*A imaging software (Soft Imaging System, Münster, Germany). Rabbit anti-insulin (sc-9168, Santa Cruz Biotechnology, Inc.) polyclonal antibody (1:500 dilution) was used for immunohistochemical staining of the beta cells. The average area of the stained islets (n = 5-15/slide) was analyzed with ImageJ 1.48v (National Institute of Health, USA). The number of islets in a representative slide was calculated, and the islets were grouped according to their size.
Statistical analyses
The results were analyzed with unpaired Student's t-test to compare the genotype differences or two-way ANOVA and Bonferroni post hoc test to compare two genotypes and an additional challenge. Two-way ANOVA for repeated measures was used to analyze parameters over The results are expressed as means ± s.e.m. P < 0.05 was considered statistically significant.
Results
Study 1. OE-NPY DBH induces hepatosteatosis and hypercholesterolemia
Hepatosteatosis in OE-NPY DBH mice develops with age. The livers of OE-NPY DBH male mice were heavier than those of WT controls at 4 and 7 months, but only at 7 months in females (Table 1) . Hepatic lipid accumulation was detected in both sexes, and ballooning degeneration in 4-and 7-month-old male OE-NPY DBH mice ( Fig. 1A and B). Hepatosteatosis was confirmed at 7 months by ORO staining and biochemical TG analysis ( Fig. 1B and C). Infarcted areas (microscopic) were detected in two of four OE-NPY DBH mice, but no visible inflammation or fibrosis. Liver of obese male OE-NPY DBH mice was graded as type 3 hepatosteatosis.
Serum total cholesterol of 7-month-old male OE-NPY DBH mice was significantly increased and there was a similar trend already at 4 months in males and at 7 months in females (Table 2) . LDL cholesterol was not changed, but HDL cholesterol was increased (Table 2) .
Study 2. Mechanisms leading to metabolic syndrome-like phenotype in OE-NPY DBH mice
OE-NPY DBH attenuates hepatic FA oxidation To study the possible mechanisms leading to hepatosteatosis, hepatic gene expression profiles were compared between pre-obese OE-NPY DBH and WT mice by microarray analysis, which showed 27 upregulated and 12 downregulated genes in OE-NPY DBH livers (Table 3) Liver weights were measured from 2-(n = 6-9/group), 4-(n = 5-6/group) and 7-month-old (n = 9-11/group) homozygous female and male OE-NPY DBH vs wild-type mice. Values are expressed as means ± s.e.m. Statistics were analyzed with Student's t-test. ND = Not diagnosed, NS = non-significant. 
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contributing in eight upregulated and five downregulated biological pathways, respectively (Table  4) . Downregulated PPAR signaling and FA metabolism pathways pointed to decreased hepatic FA oxidation in OE-NPY DBH mice. In the cluster analysis, three clusters that separated the genes with similar actions were detected: retinol, arachidonic acid and linoleic acid metabolism; FA oxidation; metabolic pathways with anti-inflammatory actions (Table 5) .
The most relevant genes involved in FA metabolism were selected for qPCR analysis to validate attenuated FA oxidation in OE-NPY DBH mice. Oxidative enzymes acyl-Coenzyme A oxidase 1 (Acox1) and carnitine acetyltransferase (Crat) were significantly decreased in pre-obese OE-NPY DBH mice ( Fig. 2A) . Decreased FA oxidation was confirmed by beta-oxidation assay (Fig. 2B) . In contrast, in obese hepatosteatotic OE-NPY DBH mice an increase in Fas and a tendency in acetyl Co-A carboxylase (Acc) expression suggested increased lipogenesis, but enzymes of beta-oxidation were not significantly different ( Fig. 2A) .
Oxidative stress precedes hepatosteatosis in OE-NPY DBH mice In the hepatic microarray analysis, pathways involved in metabolism of xenobiotics by cytochrome P450, drug metabolism and glutathione metabolism were upregulated ( Table 4 ), indicating that anti-inflammatory actions were recruited in the pre-obese liver. Accordingly, mRNA expression of proinflammatory cytokines, transforming growth factor beta 1 (Tgfb1), tumor necrosis factor alfa (Tnfa) and interleukin 1 beta (Il1b), were decreased. In the steatotic livers, proinflammatory cytokine expression was still downregulated fitting with the absence of inflammatory cells and fibrosis despite of steatosis. In contrast, 8-isoprostane, a marker of lipid peroxidation, was increased. Other markers of oxidative stress, diene conjugates, GSH or GSSG levels or GSH/GSSG ratio were not changed. Anti-inflammatory cytokine IL10 tended to be decreased (P = 0.06) in serum from pre-obese male OE-NPY DBH mice. In obese male mice resistin levels were increased, but IL6, IL10, adiponectin or markers of oxidative stress were not changed. Interestingly, adiponectin was increased in female OE-NPY DBH mice, which may explain their less prominent metabolic disturbances. Urinary oxidative stress markers were unchanged (Table 6 ).
Enhanced cholesterol synthesis precedes hypercholesterolemia in OE-NPY DBH mice Obese female OE-NPY DBH mice, representing a phenotype with hypercholesterolemia but less pronounced hepatosteatosis than the males, showed a tendency to accelerated cholesterol and bile acid synthesis in fecal analysis ( Fig. 3A and B), which directly measures the whole body cholesterol metabolism. Enhanced cholesterol synthesis was confirmed by increased mRNA expression of cholesterol synthesis enzymes 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr), farnesyl diphosphate farnesyl transferase 1 (Fdft1) and 7-dehydrocholesterol reductase (Dhcr7) in both pre-obese and obese male OE-NPY DBH mice. mRNA expression of LDL-receptor (Ldlr) was not changed, but HDL transporter, scavenger receptor B1 (Srb1), was slightly decreased (P = 0.08) in obese mice (Fig. 3C) . Cholesterol absorption was not changed (Fig. 3D and E) . DBH  mice  show  glucose-induced  hyperinsulinemia  and  hepatic  glycogen  accumulation Glucose-induced insulinemia was analyzed in vivo to study whether the previously observed IGT resulted from NPY-induced inhibition of insulin release or whole body IR. Insulin levels were markedly higher in OE-NPY DBH mice when glucose levels were still comparable to WT supporting IR ( Fig. 4A  and B) . In pyruvate challenge, OE-NPY DBH mice showed decreased gluconeogenesis when statistically significant difference in GTT was not yet revealed, but when IGT was established, there was no difference in PTT or expression of gluconeogenic enzymes ( Fig. 4C and E). The average size of islets of Langerhans in obese OE-NPY DBH mice was enlarged (WT 0.013±0.001 mm 2 ; OE-NPY DBH 0.020 ± 0.002 mm 2 ; P < 0.001) supporting previously detected hyperinsulinemia. Furthermore, obese OE-NPY DBH mice displayed hepatic glycogen accumulation (Fig. 4F ) preceded by increased expression of both glycogen synthase (Gys2) and phosphorylase (Pygl) (Fig. 4E) , which suggest acceleration of glycogen cycling.
OE-NPY
Study 3. OE-NPY DBH increases susceptibility to STZ-induced diabetes
Susceptibility to T2D was studied by subjecting 16-weekold OE-NPY DBH and WT mice to high caloric diet and low doses of STZ. Both genotypes gained weight and fat mass similarly ( Fig. 5A and B) . Fasting (4 h) glucose was significantly increased in OE-NPY DBH mice and showed Up-and downregulated genes were measured in the livers of 2-month-old heterozygous OE-NPY DBH vs wild-type mice (n = 4/group) by limma of the R statistical analysis program. Genes were considered significantly up-or downregulated when P < 0.05. FC = fold change.
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diabetic levels (over 13.8 mmol L −1 in mice) after 4 weeks of the first STZ administration (Fig. 5C ). Glucose clearance in GTT was decreased in OE-NPY DBH when compared to WT mice (Fig. 5D ) but diet-induced IR was evident in both genotypes (Fig. 5E ). Fasting serum insulin levels were equally low (Fig. 5F ), and there was no difference between the genotypes in the amount, size or intensity of insulin antibody stained areas in pancreas ( Fig. 5G and H) . Livers of OE-NPY DBH mice were non-significantly enlarged (WT 1.59 ± 0.08 g; OE-NPY DBH 1.90 ± 0.14 g; P = 0.08) and relative liver weights correlated positively with mean fasting blood glucose values (P < 0.001, r 2 = 0.62). Both genotypes showed severe hepatosteatosis, but not steatohepatitis (data not shown).
Study 4. Hepatic beta1-adrenoceptors but not Y-receptors contribute to the phenotype of OE-NPY DBH mice
Contribution of increased sympathetic NPY and modulated catecholamine release on the phenotype of OE-NPY DBH mice was first evaluated by analyzing hepatic mRNA expression of Y1 (Y1r), Y2 (Y2r), beta1-(Adrb1) and beta2-adrenergic (Adrb2) receptors. Y1r and Adrb2 expressions were similar between genotypes, but Adrb1 expression was decreased in OE-NPY DBH mice (Fig. 6A) . Y2r was undetected. Y1-receptor mediated actions of NPY were further elucidated with chronic peripheral Y1R-antagonist treatment. Y1R-antagonist did not prevent the phenotype, i.e. obesity, hepatosteatosis, IR, hyperinsulinemia, hypercholesterolemia or oxidative stress, in OE-NPY DBH mice, nor had an effect on food intake (Fig. 6B-I and Table 7 ). However, in WT mice it decreased serum TGs and increased liver cholesterol ( Fig. 6E and H) . EE (relative to lean mass), RER and total activity were similar in both treatment groups after 1-(data not shown) and 7-daytreatment (Fig. 6J , K and L).
Discussion
We have previously shown that homozygous OE-NPY DBH mice develop obesity, IGT and IR . In this study, we show that they also develop hepatosteatosis and hypercholesterolemia, and that this phenotype renders them susceptible to T2D. We previously published that the mechanism of obesity in OE-NPY DBH mice lies mostly in decreased sympathetic signaling in adipose tissues ). The current work shows that changes in hepatic lipid, glucose and cholesterol metabolism, and oxidative stress precede obesity, and suggests that decreased sympathetic signaling also in the Pathway analysis was based on the microarray analysis in the livers of 2-month-old heterozygous OE-NPY DBH vs wild-type mice (n = 4/group).
The analysis was performed with DAVID Bioinformatics Resources. FDR = False discovery rate (%), an adjusted P value, which estimates the probability of significant P value (<0.05) being false. Cluster analysis was based on the microarray analysis in the livers of 2-month-old heterozygous OE-NPY DBH vs wild-type mice (n = 4/group).
The analysis was performed with DAVID Bioinformatics Resources. Biological pathways are clustered into homogenous clusters which differ from other clusters: the higher score of the cluster, the higher homogeneity within the cluster. FDR = False discovery rate (%), adjusted P value, which estimates the probability of significant P value (<0.05) being false.
liver importantly contributes to the development of the metabolic disturbances in OE-NPY DBH mice. Serum cytokine levels and hepatic mRNA expression were analyzed from 2-(pre-obese) (n = 3-9/group) and 7-month-old (obese) (n = 4-10/group) male OE-NPY DBH vs wild-type mice. Oxidative stress markers in plasma, urine and liver were measured from 5-month-old male OE-NPY DBH vs wild-type mice (n = 8-9/group). Serum resistin and adiponectin were measured from 7-month-old female and male OE-NPY DBH vs wild-type mice (n = 8-10/group). Values are expressed as means ± s.e.m. Statistics were analyzed with Student's t-test. ND = Not diagnosed, IL6 = Interleukin 6, IL10 = Interleukin 10, TRAP = Total peroxyl radical trapping antioxidant potential, GSH = Glutathione, GSSG = glutathione disulfide, Il1b = Interleukin 1 beta, Tnfa = Tumor necrosis factor alfa, Tgfb1= Transforming growth factor beta 1.
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but suppressed lipolysis, decreased serum TG and nonesterified FA levels and simultaneous accumulation of TGs into the liver and WAT argue against increased flux of lipids from WAT to the liver . Hepatic TG accumulation in obese OE-NPY DBH mice develops into type 3 hepatosteatosis characterized by lipid droplets and ballooning degeneration without inflammation and fibrosis. However, markers of inflammation were detected both in pre-obese and obese states, which together with hepatosteatosis may contribute to the development of IR and T2D in OE-NPY DBH mice. The upregulated anti-inflammatory pathways in pre-obese livers, usually considered a secondary response to oxidative stress, may be an early sign of disruptions in hepatic FA metabolism. 8-Isoprostane, a marker for oxidative stress (reviewed by (Roberts & Morrow 2000) ), was elevated in steatotic livers. Decreased levels of anti-inflammatory cytokine IL10 in pre-obese state may also promote metabolic disturbances, as IL10 has been shown to protect from hepatosteatosis and IR (Dagdeviren et al. 2016 , Paredes-Turrubiarte et al. 2016 . Furthermore, although inflammatory cells were not present in expanding WAT , we detected elevated levels of resistin, whose production has previously been shown to be stimulated by NPY in WAT (Yuzuriha et al. 2003 , Kuo et al. 2007 . Resistin can independently induce IGT and IR (Steppan et al. 2001 , Rajala et al. 2003 , and it associates with T2D, obesity and inflammation (McTernan et al. 2003 , Shetty et al. 2004 , Fu et al. 2006 . Interestingly, we also detected decreased expression of cytokines (Il1b, Tnfa and Tgfb1), usually associated with the development of steatohepatitis. Decreased FA oxidation, (i.e. decreased production of ROS) or cytokine-independent oxidative stress may explain this discrepancy to our other results. Presumably NPY has anti-inflammatory effects (Wheway et al. 2005 , Ferreira et al. 2010 , but it has also been shown to be upregulated in human hepatosteatosis and to be involved in the development of fibrosis (Sigala et al. 2013 , Zhu et al. 2015 . Together with our results they suggest that NPY has a dual role in inflammation.
NPY variant (rs16139) is associated with hypercholesterolemia and atherosclerosis (Karvonen et al. 1998 , and in consistence, obese OE-NPY DBH mice showed elevated serum total and HDL cholesterol together with a tendency of decreased HDL-receptor, Srb1, expression, which all associate with T2D or atherosclerosis in mice (Nishina et al. 1994 , Kozarsky et al. 2000 . VLDL/ LDL fraction was not changed, which may be influenced by decreased serum TGs, the main component of VLDL, Cholesterol metabolism in OE-NPY DBH mice. (A) Cholesterol and (B) bile acid synthesis in 6-month-old homozygous female OE-NPY DBH vs wild-type mice measured by fecal ratio method (n = 5-10/group). (C) mRNA expression of cholesterol and bile acid synthesis enzymes in 2-month-old heterozygous (pre-obese) (n = 5/ group) and 7-month-old homozygous (obese) (n = 10/group) OE-NPY DBH mice relative to wild-type mice. Beta actin was used as endogenous control. (D) Cholesterol absorption measured by fecal ratio method and (E) mRNA expression of jejunal cholesterol influx and efflux proteins in 6-month-old homozygous female OE-NPY DBH mice relative to wild-type mice (n = 7-9/group). Beta actin was used as endogenous control. Values are expressed as means ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 with Student's t-test. Hmgcr = 3-hydroxy-3-methylglutaryl-CoA reductase, Fdft1 = farnesyl diphosphate farnesyl transferase 1, Dhcr7 = 7-dehydrocholesterol reductase, Ldlr = LDL-receptor, Srb1 = Scavenger receptor, class B, type 1, Cyp7a1 = cytochrome P450 7a1, Npc1l1 = Niemann-Pick C1-Like 1, Acat2 = acetyl-Coenzyme A acetyltransferase 2, Abca1 = ATP-binding cassette A1, Abcg5 = ATPbinding cassette G5, Abcg8 = ATP-binding cassette G8, WT = wild-type mice, OE-NPY = OE-NPY DBH mice.
previously observed in these mice . The mechanism of hypercholesterolemia in OE-NPY DBH mice is elevated cholesterol synthesis without a change in cholesterol absorption. As this is detected already in preobese state, thus without agitation of hepatosteatosis or the metabolic syndrome (Gylling et al. 2007 , Simonen et al. 2011 , we suggest that the hepatic cholesterol synthesis is elevated by noradrenergic NPY and explains the hypercholesterolemia of obese OE-NPY DBH mice.
The mechanism of IGT, previously detected in OE-NPY DBH mice , was scrutinized in states of early and in established obesity. In the early stage, OE-NPY DBH mice seem to compensate elevated blood glucose levels effectively by increasing insulinemia and by restoring excess energy to glycogen and TGs by the liver. This was demonstrated by almost absent pyruvate-induced increase in glucose levels, and by increased glycogen metabolism known to associate with T2D (Hundal et al. 2000) . Based on previous findings (Cho & Kim 2004 , Machida et al. 2014 , NPY unlikely increases pancreatic insulin secretion directly, and glucose-induced hyperinsulinemia in OE-NPY DBH mice is rather secondary to systemic IR. With aging, IGT, IR and fasting hyperinsulinemia with enlarged pancreatic islets, and hepatic glycogen accumulation, as shown here, become evident. To test whether this phenotype similar to carriers of rs16139 (Ukkola & Kesaniemi 2007 , Jaakkola et al. 2009 , Nordman et al. 2005 renders OE-NPY DBH mice susceptible to T2D, the mice were exposed to low-dose STZ to interfere with pancreatic beta cells less than in the traditional T1D STZ-model, and high caloric diet to induce IR (Gilbert et al. 2011) . Only OE-NPY DBH mice reached diabetic fasting blood glucose levels, thus showing higher susceptibility to T2D. They also showed augmented response in GTT, despite comparably low fasting insulin levels and severe IR as WT mice. However, it is presumable that glucose-stimulated insulin release was impaired in OE-NPY DBH mice, and likely with a higher insulin dose or a more sensitive method to assess insulin sensitivity, more severe IR would have been detected in OE-NPY DBH mice.
Previously, the effects of NPY on hepatic metabolism have mostly been attributed to central, hypothalamic effects (Zarjevski et al. 1993 , Stafford et al. 2008 , but also peripheral effects are possible (Zhang et al. 2010 , Xie et al. 2012 . In order to elucidate whether the observed changes in OE-NPY DBH mice are due to NPY's direct effect in the liver, or altered SNS activity, hepatic NPY and adrenergic receptor expressions were analyzed. As presence of hepatic Glucose metabolism in OE-NPY DBH mice. (A) Glucose tolerance test and (B) glucose-induced hyperinsulinemia in 4-month-old homozygous OE-NPY DBH vs wild-type mice (n = 7/group). (C) Glucose (D) and pyruvate tolerance tests of 4-month-old and 7-month-old homozygous OE-NPY DBH vs wild-type mice (n = 6-11/group). (E) mRNA expression of selected genes involved in glucose metabolism in 2-month-old heterozygous (pre-obese) (n = 5/group) and 7-month-old homozygous (obese) (n = 10/group) OE-NPY DBH mice relative to wild-type mice. Beta actin was used as endogenous control. (F) Representative periodic acid-Schiff stained liver slides showing glycogen accumulation into the hepatocytes in 7-month-old OE-NPY DBH vs wild-type mice (scale bar 50 µm). Values are expressed as means ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 with two-way ANOVA of repeated measures (A-D) or Student's t-test (E). GTT = glucose tolerance test, PTT = pyruvate tolerance test, Pck1 = phosphoenolpyruvate carboxykinase 1, Pgc1a = peroxisome proliferative activated receptor, gamma, coactivator 1 alpha, Gys2 = Glycogen synthase 2, Pygl = liver glycogen phosphorylase, WT = wild-type mice, OE-NPY = OE-NPY DBH mice.
Y1-receptors (but not Y2-receptors) was detected, and peripheral Y1-receptor knockdown has previously shown beneficial effects on hepatic FA metabolism (Zhang et al. 2010) , their contribution was studied by chronic treatment with a peripheral Y1R-antagonist, BIBO3044. Opposite to our hypothesis, Y1R-antagonist was unable to prevent the metabolic phenotype of OE-NPY DBH mice. Thus, in the model of excess noradrenergic NPY, peripheral Y1-receptors seem to play a minor role in the phenotype. Furthermore, in WT mice, peripheral Y1-receptor antagonism did not produce similar beneficial effects, e.g. increased FA oxidation, as Y1-receptor knockdown. In contrast, reduced serum TGs and increased hepatic cholesterol point to metabolic disturbances similar to what is seen in OE-NPY DBH mice and high fat diet-fed mice (Gao et al. 2010) .
Attenuated SNS activity in adipose tissue was previously shown to contribute to obesity in OE-NPY DBH mice, and therefore similar actions in the liver were considered as another probable mechanism. A significant decrease in Adrb1 expression both in heterozygous and homozygous OE-NPY DBH mice was detected, although they display opposite effects of NPY overexpression on catecholamine levels with heterozygous showing increased and homozygous mice decreased sympathetic tone (Ruohonen et al. 2008 . Despite this discrepancy, the metabolic phenotype is similar, albeit more pronounced in the homozygous model. 
Pixels
Figure 5
Type 2 diabetes model in OE-NPY DBH mice. (A) Weight gain, (B) whole body fat mass %, (C) fasting blood glucose, (D) glucose and (E) insulin tolerance tests, (F) fasting serum insulin levels, (G) quantitated pancreatic insulin intensity, and (H) the amount and size of beta cells in homozygous OE-NPY DBH vs wild-type mice (n = 7/group) subjected to high caloric diet from age of 13 weeks and low-dose streptozotocin from age of 16 weeks (Week 0) onwards.
Values are expressed as means ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 with two-way ANOVA and Bonferroni post hoc test (B) or two-way ANOVA of repeated measures (C-D). Gray dashed line = glucose 13.8 mmol L −1 , the limit for diabetes in mice, STZ = streptozotocin, GTT = glucose tolerance test, ITT = Insulin tolerance test, WT = wild-type mice, OE-NPY = OE-NPY DBH mice. Roles of NPY and adrenergic receptors in OE-NPY DBH mice. (A) mRNA expression of liver NPY-and adrenergic receptors in 2-month-old heterozygous (pre-obese) (n = 4-5/group) and 7-month-old homozygous (obese) (n = 6-7/group) OE-NPY DBH mice relative to wild-type mice. Beta actin was used as endogenous control. (B) Weight gain, (C) fat mass gain, (D) cumulative food intake, (E-F) serum lipids, (G-H) liver lipids and I) liver 8-isoprostane in OE-NPY DBH vs wild-type mice (n = 10-13/group) treated with Y1R-antagonist BIBO3044 or vehicle for 4 weeks. (J) Energy expenditure, (K) respiratory exchange ratio and (L) physical activity of wild-type mice (n = 4/group) treated with Y1R-antagonist or vehicle for 1 week. Values are expressed as means ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 difference between genotypes with Student's t-test (A, H and I) or with two-way ANOVA and Bonferroni post hoc test (B-D and F-G). # P < 0.05 and ## P < 0.01 difference between treatments within a same genotype with two-way ANOVA and Bonferroni post hoc test (E and H), or with two-way ANOVA of repeated measures (L). Adrb1 = adrenergic-beta1-receptor, Adrb2 = adrenergic-beta2-receptor, Y1r = Y1-receptor, EE = energy expenditure, RER = respiratory exchange ratio, WT = wild-type mice, OE-NPY = OE-NPY DBH mice. Glucose metabolism parametres were measured from 6-month-old homozygous male OE-NPY DBH vs wild-type mice (n = 10-13/group) treated with Y1R-antagonist (BIBO3044) or vehicle for 4 weeks. Values are expressed as means ± s.e.m. *P < 0.05 and **P < 0.01 between genotypes in vehicle treated groups with Student's t-test.
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However, decreased Adrb1 expression points to suppressed sympathetic action in the liver, which may explain the locally induced metabolic changes. Low catecholamines have been reported to increase lipogenesis in WAT, and Adrb1 deficiency to induce IGT and IR, and to increase susceptibility to obesity and hepatosteatosis on a high fat diet (Ueta et al. 2012) providing additional support for our theory.
In conclusion, OE-NPY DBH mice develop obesity, IGT, IR, hepatosteatosis and hypercholesterolemia, and when pancreatic insulin production is disrupted, also T2D. The model reveals that NPY expressed in the noradrenergic neurons has potent metabolic effects in the WAT and the liver, which support energy conservation and storage. Our results suggest that the effects on WAT and liver are mediated mostly via inhibition of SNS in OE-NPY DBH mice, and that peripheral Y1-receptor mediated actions are less important, at least in the liver. The findings from OE-NPY DBH mice may be relevant to the mechanisms of stress-induced obesity and the metabolic disorders associated with the gain-of-function NPY polymorphisms.
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